

# Casey R Ager

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7423789/casey-r-ager-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12  
papers

445  
citations

9  
h-index

15  
g-index

15  
ext. papers

696  
ext. citations

15.4  
avg, IF

3.38  
L-index

#	Paper	IF	Citations
12	758 High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma <b>2021</b> , 9, A793-A793		
11	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , <b>2021</b> , 184, 2988-3005.e16	56.2	15
10	Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 608-621	12.9	17
9	Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 529-541	12.5	1
8	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege <b>2021</b> , 9,		7
7	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 1365-1380	12.5	13
6	Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 126640	2.9	15
5	TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma <b>2019</b> , 7, 323		29
4	Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1138-1151	12.9	36
3	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 5137-5149	15.9	159
2	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 676-684	12.5	91
1	Expanding the product profile of a microbial alkane biosynthetic pathway. <i>ACS Synthetic Biology</i> , <b>2013</b> , 2, 59-62	5.7	61